Drugs / RP903
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06846099 | Dec 2022 → May 2025 | breast cancer, cervical cancer, endometrial cancer, ovarian cancer | Risen (Suzhou) Pharma Tech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP903 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06846099 ↗ |
| Known as | JS105 | “Pl3Kα-Selective Inhibitor RP903 (JS105)” NCT06846099 ↗ |
| Action | Inhibit | “Pl3Kα-Selective Inhibitor” NCT06846099 ↗ |
| Route | Oral | “po qd” NCT06846099 ↗ |